The concern of generic challenges has long loomed over copyright’s famous drug, Sildenafil, triggering questions about the prospects of related pharmaceutical portfolios. While initial times saw substantial profits, the intellectual property lapse has allowed the path for less expensive copies, potentially lowering earnings and posing a significa